Table 2.
Association of early BP treatment pattern, ASCVD events, and cardiovascular and all-cause mortality
| SBP at treatment initiation (mmHg) | On-treatment SBP (mmHg) | Unadjusted incidence rate (95% CI)* | Adjusted incidence rate (95% CI)*† | Adjusted IRD (95% CI)*† |
|---|---|---|---|---|
| ASCVD | ||||
| 130–139 | 100–119 | 7.2 (5.2, 9.9) | 7.8 (5.4, 11.4) | −0.1 (−2.0, 2.0) |
| 120–129 | 7.2 (6.0, 8.6) | 7.9 (6.5, 9.7) | Reference | |
| 130–139 | 9.0 (7.9, 10.3) | 9.8 (8.6, 11.3) | 1.9 (0.6, 3.2) | |
| 140–159 | 12.4 (10.7, 14.4) | 12.4 (10.7, 14.3) | 4.5 (2.9, 6.1) | |
| ≥140 | 100–119 | 7.3 (5.9, 8.9) | 7.6 (6.2, 9.4) | −0.3 (−1.8, 1.1) |
| 120–129 | 8.6 (7.7, 9.5) | 8.9 (8.1, 9.9) | 1.0 (−0.2, 2.1) | |
| 130–139 | 8.9 (8.3, 9.5) | 9.1 (8.5, 9.8) | 1.1 (0.04, 2.2) | |
| 140–159 | 11.9 (11.2, 12.6) | 11.2 (10.5, 11.9) | 3.2 (2.1, 4.3) | |
| CVD mortality | ||||
| 130–139 | 100–119 | 3.5 (2.2, 5.5) | 4.2 (2.6, 6.7) | 1.4 (0.5, 2.4) |
| 120–129 | 2.3 (1.7, 3.1) | 2.8 (2.0, 3.9) | Reference | |
| 130–139 | 2.4 (1.8, 3.0) | 2.7 (2.1, 3.6) | −0.06 (−0.6, 0.5) | |
| 140–159 | 3.2 (2.4, 4.2) | 3.1 (2.3, 4.1) | 0.3 (−0.3, 0.9) | |
| ≥140 | 100–119 | 3.6 (2.8, 4.8) | 3.7 (2.8, 4.9) | 0.9 (0.2, 1.5) |
| 120–129 | 3.2 (2.7, 3.7) | 3.6 (3.0, 4.2) | 0.8 (0.3, 1.2) | |
| 130–139 | 3.6 (3.2, 4.0) | 3.7 (3.3, 4.1) | 0.9 (0.4, 1.3) | |
| 140–159 | 4.8 (4.3, 5.2) | 4.1 (3.7, 4.5) | 1.3 (0.8, 1.7) | |
| All-cause mortality | ||||
| 130–139 | 100–119 | 12.1 (9.5, 15.4) | 14.4 (11.2, 18.5) | 2.8 (0.08, 5.7) |
| 120–129 | 8.9 (7.7, 10.4) | 11.6 (9.9, 13.7) | Reference | |
| 130–139 | 9.0 (7.9, 10.2) | 10.5 (9.2, 12.0) | −1.1 (−2.7, 0.5) | |
| 140–159 | 11.9 (10.3, 13.7) | 11.7 (10.1, 13.5) | 0.1 (−1.7, 1.9) | |
| ≥140 | 100–119 | 15.4 (13.5, 17.6) | 15.1 (13.2, 17.3) | 3.5 (1.5, 5.5) |
| 120–129 | 12.8 (11.8, 13.8) | 14.1 (13.0, 15.3) | 2.5 (1.0, 4.0) | |
| 130–139 | 12.0 (11.3, 12.7) | 12.3 (11.6, 13.1) | 0.7 (−0.7, 2.0) | |
| 140–159 | 14.9 (14.2, 15.7) | 13.1 (12.4, 13.8) | 1.5 (0.05, 2.8) |
CVD, cardiovascular disease.
*Incidence rates and IRDs in events/1,000 person-years.
†Adjusted models included age, sex, race, ethnicity, non-HDL cholesterol, BMI, smoking status, outpatient diabetes medications (categorized as none, drug regimens without insulin, and drug regimens with insulin), baseline HbA1c, renal function expressed as the eGFR calculated using the Chronic Kidney Disease Epidemiology Collaboration equation, Elixhauser comorbidity index score, and time-varying renal function, time-varying HbA1c, and time-varying Elixhauser comorbidity index score during the first 2 years on antihypertensive treatment.